Israel’s Silexion Therapeutics (see here previously) received Israeli Ministry of Health approval to initiate a Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, marking advancement to clinical-stage development. SIL204 targets a range of common KRAS mutations.
Pancreatic cancer treatment ready for trials
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.